| Literature DB >> 30360478 |
Inese Sviestina1,2, Dzintars Mozgis3.
Abstract
Background and objectives: Many pediatric patients have been treated with antibiotics during their hospitalization. There is a need to improve antibiotic prescribing for pediatric patients because many of these prescriptions are inappropriate. Antibiotic consumption analysis was conducted at the Children's Clinical University Hospital to identify targets for quality improvement. Materials andEntities:
Keywords: defined daily dose; hospitalized children; parenteral antibiotics; point prevalence survey; third-generation cephalosporins
Mesh:
Substances:
Year: 2018 PMID: 30360478 PMCID: PMC6262611 DOI: 10.3390/medicina54050074
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
CCUH patients’ characteristics (2011–2013).
| Year | 2011 | 2012 | 2013 | 2011 | 2012 | 2013 |
|---|---|---|---|---|---|---|
| Month | May | May | May | November | November | November |
| Patients | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
| Total number | 418 | 395 | 335 | 424 | 358 | 320 |
| Male | 230 (55) | 215 (54) | 178 (53) | 225 (53) | 196 (55) | 159 (50) |
| Female | 188 (45) | 180 (46) | 157 (47) | 199 (47) | 162 (45) | 161 (50) |
| Patients on antibiotics | 125 (30) | 128 (32) | 88 (26) | 159 (38) | 130 (36) | 111 (35) |
| Gender: | ||||||
| Male | 63 (50) (42–59) | 59 (46) (38–55) | 47 (53) (43–64) | 90 (57) (49–63) | 74 (57) (48–65) | 57 (51) (42–61) |
| Female | 62 (50) (41–58) | 69 (54) (45–63) | 41 (47) (36–57) | 69 (43) (36–51) | 56 (43) (35–52) | 54 (49) (39–58) |
| Age groups: | ||||||
| 0–<1 month | 20 (16) | 10 (8) | 10 (11) | 19 (12) | 12 (9) | 19 (17) |
| ≥1 month–<1 year | 14 (11) | 27 (21) | 13 (15) | 24 (15) | 21 (16) | 20 (18) |
| ≥1–<5 years | 52 (42) | 33 (26) | 32 (36) | 54 (34) | 36 (28) | 24 (22) |
| ≥5–<12 years | 27 (22) | 29 (3) | 14 (16) | 33 (21) | 35 (27) | 27 (24) |
| ≥12–<18 years | 12 (10) | 29 (23) | 19 (20) | 29 (19) | 26 (20) | 21 (19) |
| How many antibiotics received one patient: | ||||||
| 1 antibiotic | 108 (86) | 102 (79) | 69 (79) | 141 (88) | 102 (79) | 95 (85) |
| 2 antibiotics | 17 (14) | 23 (18) | 15 (17) | 8 (5) | 23 (18) | 12 (11) |
| 3 antibiotics | 0 | 2 (2) | 3 (3) | 6 (4) | 2 (1) | 2 (2) |
| 4 antibiotics | 0 | 1 (1) | 1 (1) | 4 (3) | 3 (2) | 1 (1) |
| 5 antibiotics | 0 | 0 | 0 | 0 | 0 | 1 (1) |
Antibiotic groups used during PPSs in 2011–2013 and the route of administration.
| Year | 2011 | 2012 | 2013 | 2011 | 2012 | 2013 |
|---|---|---|---|---|---|---|
| Month | May | May | May | November | November | November |
| Antibiotics (prescriptions): | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
| Total N of prescriptions | 142 | 157 | 106 | 192 | 162 | 132 |
| Aminoglycosides (J01G) | 11 (8) | 15 (10) | 9 (9) | 11 (6) | 13 (8) | 12 (9) |
| β-lactam AB, penicillins (J01C) | 51 (35.9) | 46 (29.3) | 32 (30.2) | 65 (34) | 49 (30) | 23 (17) |
| Macrolides and lincosamides (J01F) | 8 (6) | 6 (4) | 6 (6) | 12 (6.3) | 12 (7.4) | 9 (6.8) |
| Other β-lactam AB (J01D) | 46 (32) | 66 (42) | 42 (40) | 63 (33) | 67 (41) | 54 41) |
| Quinolones (J01M) | 1 (1) | 3 (2) | 2 (2) | 0 | 0 | 5 (4) |
| Other AB (J01X) | 7 (5) | 10 (6) | 7 (7) | 17 (9) | 9 (6) | 10 (8) |
| Sulfonamides and trimethoprim (J01E) | 18 (13) | 11 (7) | 8 (8) | 24 (13) | 12 (7) | 19 (14) |
| Six most often used antibiotics: | ||||||
| Ampicillin | 25 (18) | 10 (6) | 9 (8) | 17 (9) | 5 (3) | 6 (5) |
| Ceftriaxone | 12 (8) | 13 (8) | 16 (15) | 19 (10) | 25 (15) | 23 (17) |
| Amoxicillin | 11 (8) | 19 (12) | 8 (8) | 22 (11) | 21 913) | 7 (5) |
| Cefuroxime | 9 (6) | 22 (14) | 9 (8) | 12 (6) | 18 (11) | 15 (14) |
| Sulfamethoxazole & trimethoprim | 18 (13) | 11 (7) | 8 (8) | 24 (13) | 12 (7) | 15 (14) |
| Penicillin G | 14 (10) | 11 (7) | 11 (10) | 19 (10) | 17 (10) | 8 (6) |
| Route of administration: | ||||||
| Intravenous | 108 (76) | 135 (86) | 91 (86) | 146 (76) | 131 (81) | 100 (76) |
| Oral | 34 (24) | 22 (14) | 15 (14) | 46 (24) | 31 (19) | 32 (24) |
Figure 1Reason of antibiotic use in PPSs during the period of 2011–2013.
Antibiotic groups used during the period of 2006–2015 and 2017 (DDD/100 BD and DDD/100 inpatients).
| Year | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DDD/100 BD: | |||||||||||
| Aminoglycosides (J01G) | 3.9 | 4.0 | 3.3 | 3.3 | 2.5 | 3.3 | 3.0 | 3.6 | 3.5 | 2.3 | 2.3 |
| β-lactam AB, penicillins (J01C) | 23.0 | 24.2 | 19.7 | 20.4 | 22.0 | 22.0 | 19.8 | 19.7 | 14.2 | 18.7 | 21.2 |
| Macrolides and lincosamides (J01F) | 1.3 | 2.1 | 1.2 | 1.0 | 1.4 | 1.9 | 3.4 | 3.5 | 2.6 | 8.1 | 4.9 |
| Other β-lactam AB (J01D) | 6.8 | 10.3 | 9.2 | 8.3 | 9.4 | 11.2 | 12.2 | 16.4 | 16.7 | 15.7 | 16.8 |
| Quinolones (J01M) | 0.7 | 1.3 | 0.5 | 0.3 | 0.5 | 1.8 | 0.6 | 0.9 | 1.9 | 1.4 | 1.0 |
| Tetracyclines (J01A) | 0.2 | 0.5 | 0.6 | 0.4 | 0.5 | 0.6 | 0.4 | 0.2 | 0.4 | 0.3 | 0.2 |
| Other AB (J01X) | 1.9 | 2.7 | 1.1 | 2.2 | 2.3 | 2.4 | 3.3 | 4.0 | 3.4 | 4.3 | 5.2 |
| Sulfonamides and trimethoprim (J01E) | 1.6 | 1.6 | 2.0 | 2.1 | 1.8 | 0.5 | 0.4 | 0.8 | 3.2 | 2.4 | 2.7 |
| DDD/100 inpatients: | |||||||||||
| Aminoglycosides (J01G) | 22 | 22 | 19 | 18 | 18 | 16 | 13 | 15 | 18 | 12 | 11 |
| β-lactam AB, penicillins (J01C) | 131 | 136 | 112 | 107 | 111 | 90 | 88 | 82 | 74 | 57 | 104 |
| Macrolides and lincosamides (J01F) | 7 | 12 | 7 | 5 | 7 | 9 | 15 | 15 | 13 | 16 | 24 |
| Other β-lactam AB (J01D) | 39 | 58 | 52 | 43 | 47 | 53 | 54 | 69 | 85 | 83 | 82 |
| Quinolones (J01M) | 4 | 7 | 3 | 2 | 3 | 9 | 3 | 4 | 10 | 7 | 5 |
| Tetracyclines (J01A) | 1 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | 2 | 0.3 | 1 |
| Other AB (J01X) | 11 | 15 | 6 | 12 | 12 | 11 | 15 | 17 | 18 | 22 | 25 |
| Sulfonamides and trimethoprim (J01E) | 9 | 9 | 11 | 11 | 9 | 2 | 2 | 3 | 17 | 12 | 13 |
Amoxicillin, ampicillin, penicillin G and ceftriaxone consumption during the period of 2006–2015 and 2017.
| Year | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DDD/100 BD: | |||||||||||
| Amoxicillin | 4.9 | 6.5 | 5.3 | 8.8 | 11.5 | 13.5 | 13.0 | 11.3 | 7.7 | 10.8 | 9.8 |
| Ampicillin | 8.1 | 8.6 | 6.4 | 4.0 | 2.6 | 2.4 | 2.7 | 2.7 | 2.1 | 2.7 | 3.7 |
| Penicillin G | 5.2 | 4.3 | 3.8 | 2.5 | 3.6 | 2.7 | 1.9 | 2.7 | 1.4 | 1.2 | 0.7 |
| Ceftriaxone | 1.3 | 3.9 | 3.0 | 3.2 | 3.9 | 5.0 | 5.1 | 6.7 | 7.4 | 6.7 | 4.0 |
| DDD/100 inpatients: | |||||||||||
| Amoxicillin | 27.8 | 36.5 | 29.8 | 46.2 | 57.9 | 64.7 | 56.2 | 47.1 | 40.2 | 56.8 | 47.9 |
| Ampicillin | 46.0 | 48.0 | 36.3 | 21.2 | 13.1 | 11.7 | 12.1 | 11.3 | 11.1 | 14.0 | 17.9 |
| Penicillin G | 30.0 | 25.8 | 21.7 | 13.3 | 18.0 | 13.0 | 8.3 | 11.2 | 7.3 | 6.5 | 3.5 |
| Ceftriaxone | 7.4 | 21.8 | 17.3 | 16.7 | 19.5 | 24.1 | 22.7 | 28.1 | 38.2 | 35.1 | 19.3 |
Figure 2Five most commonly used AB during the period of 2006–2015 and 2017 (90%DU).